Evolus Revenue 2016-2018 | EOLS
Evolus revenue from 2016 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| Evolus Annual Revenue (Millions of US $) |
|
|---|---|
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| Evolus Quarterly Revenue (Millions of US $) |
|
|---|---|
| Q4 2018 | $0 |
| Q3 2018 | $0 |
| Q2 2018 | $0 |
| Q1 2018 | $0 |
| Q4 2017 | $0 |
| Q3 2017 | $0 |
| Q2 2017 | $0 |
| Q1 2017 | $0 |
| Q4 2016 | $0 |
| Q4 2015 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.577B | $0.000B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $137.409B | 27.16 |
| Medtronic (MDT) | Ireland | $121.535B | 17.77 |
| Stryker (SYK) | United States | $72.819B | 26.70 |
| Boston Scientific (BSX) | United States | $52.168B | 25.43 |
| Baxter (BAX) | United States | $39.788B | 25.45 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.879B | 16.57 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $17.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.802B | 0.00 |
| ResMed (RMD) | United States | $14.533B | 27.56 |
| Aurora Cannabis (ACB) | Canada | $9.364B | 66.07 |
| Bio-Rad Laboratories (BIO) | United States | $9.204B | 52.51 |
| Hill-Rom Holdings (HRC) | United States | $6.966B | 21.55 |
| Perrigo (PRGO) | Ireland | $6.355B | 10.30 |
| Insulet (PODD) | United States | $5.761B | 1943.60 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.977B | 0.00 |
| ICU Medical (ICUI) | United States | $4.744B | 29.53 |
| Haemonetics (HAE) | United States | $4.355B | 38.63 |
| Hutchison China MediTech (HCM) | China | $3.802B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.664B | 0.00 |
| Neogen (NEOG) | United States | $3.153B | 48.42 |
| NuVasive (NUVA) | United States | $2.938B | 25.63 |
| Quidel (QDEL) | United States | $2.527B | 22.80 |
| Aphria (APHA) | $2.418B | 107.33 | |
| National Vision Holdings (EYE) | United States | $2.298B | 45.20 |
| Cardiovascular Systems (CSII) | United States | $1.337B | 960.00 |
| HEXO (HEXO) | $1.317B | 0.00 | |
| VAREX IMAGING (VREX) | United States | $1.274B | 24.95 |
| Phibro Animal Health (PAHC) | United States | $1.273B | 18.29 |
| AtriCure (ATRC) | United States | $1.095B | 0.00 |
| MacroGenics (MGNX) | United States | $0.957B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.914B | 24.70 |
| Cerus (CERS) | United States | $0.842B | 0.00 |
| Omeros (OMER) | United States | $0.836B | 0.00 |
| PetIQ (PETQ) | United States | $0.835B | 23.90 |
| NanoString Technologies (NSTG) | United States | $0.726B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.716B | 21.32 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.674B | 22.95 |
| OraSure Technologies (OSUR) | United States | $0.671B | 29.41 |
| TG Therapeutics (TGTX) | United States | $0.619B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.587B | 27.92 |
| Surmodics (SRDX) | United States | $0.556B | 80.90 |
| Quanterix (QTRX) | United States | $0.531B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.350B | 144.46 |
| Insys Therapeutics (INSY) | United States | $0.342B | 0.00 |
| Vapotherm (VAPO) | United States | $0.335B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.325B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.313B | 20.33 |
| Bovie Medical (APYX) | United States | $0.271B | 0.00 |
| Owens & Minor (OMI) | United States | $0.265B | 3.67 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.242B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.237B | 0.00 |
| Zynex (ZYXI) | United States | $0.142B | 15.21 |
| Fonar (FONR) | United States | $0.140B | 7.48 |
| Surface Oncology (SURF) | United States | $0.123B | 0.00 |
| Chimerix (CMRX) | United States | $0.103B | 0.00 |
| Female Health (VERU) | United States | $0.097B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.094B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.089B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 20.02 |
| CAS Medical Systems (CASM) | United States | $0.071B | 0.00 |
| Neurotrope (NTRP) | United States | $0.067B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.062B | 18.50 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.036B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.033B | 0.00 |
| Senestech (SNES) | United States | $0.032B | 0.00 |
| Myomo (MYO) | United States | $0.021B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.017B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 15.14 |
